{"id":390292,"date":"2019-12-30T00:00:00","date_gmt":"2019-12-30T00:00:00","guid":{"rendered":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/dlsfcg0003-2019-biopharma-migraine-disease-landscape-and-forecast-g7-2019\/"},"modified":"2026-04-15T23:23:22","modified_gmt":"2026-04-15T23:23:22","slug":"dlsfcg0003-2019-biopharma-migraine-disease-landscape-and-forecast-g7-2019","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/dlsfcg0003-2019-biopharma-migraine-disease-landscape-and-forecast-g7-2019\/","title":{"rendered":"Migraine | Disease Landscape and Forecast | G7 | 2019"},"content":{"rendered":"<p>The market for prescription migraine therapies comprises an array of prescription acute and prophylactic treatments and fosters a large and dynamic pipeline. In the acute space, we anticipate the launch of several new brands, including novel triptan and\u00a0<abbr title=\"dihydroergotamine\">DHE<\/abbr>\u00a0reformulations and promising nontriptan\u00a0<abbr title=\"new molecular entity\">NME<\/abbr>s. Among them are Eli Lilly\u2019s 5-HT1F receptor agonist lasmiditan and two oral calcitonin gene-related peptide (<abbr title=\"calcitonin gene-related peptide\">CGRP<\/abbr>) receptor antagonists\u2014Allergan\u2019s ubrogepant and Biohaven\u2019s rimegepant\u2014which together will drive strong growth in the large acute segment. However, it is the launch of four premium-priced anti-<abbr title=\"calcitonin gene-related peptide\">CGRP<\/abbr>\u00a0monoloncal antibodies\u00a0and two oral gepants for episodic and chronic migraine prevention that will be the main driver of multi-billion-dollar sales growth of this market. These drugs follow in the footsteps of Allergan\u2019s Botox (approved for chronic migraine), which has proven the commercial opportunity that new, valued brand alternatives can seize in the otherwise generic prophylaxis segment.<\/p>\n<p><strong>Questions Answered:<\/strong><\/p>\n<ul>\n<li>How will Amgen \/ Novartis\u2019s Aimovig, Teva\u2019s Ajovy, Eli Lilly\u2019s Emgality, and Lundbeck \/ Alder\u2019s eptinezumab compete with one another and with established prophylactic therapies as their marketers vie for patient share? How will the launch of two oral\u00a0<abbr title=\"calcitonin gene-related peptide\">CGRP<\/abbr>\u00a0receptor antagonists impact the migraine prophylaxis market?<\/li>\n<li>Will novel\u00a0<abbr title=\"new molecular entity\">NME<\/abbr>s lasmiditan, ubrogepant, and rimegepant gain a foothold in the heavily generic acute segment dominated by triptans?<\/li>\n<li>How will new nonoral reformulations compete for patient share with existing brands and generics in the small niche patient population in need of nonoral alternatives?<\/li>\n<\/ul>\n<p><strong>Product Description:<\/strong><\/p>\n<p>Disease Landscape &#038; Forecast provides comprehensive market intelligence with world-class epidemiology, keen insight into current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research.<\/p>\n","protected":false},"template":"","class_list":["post-390292","report","type-report","status-publish","hentry","report-gateway-biopharma","biopharma-therapy-areas-migraine","biopharma-date-931"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/390292","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"version-history":[{"count":2,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/390292\/revisions"}],"predecessor-version":[{"id":576550,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/390292\/revisions\/576550"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=390292"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}